Cargando…

Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study

INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Frix, Anne-Noelle, Heaney, Liam G., Dahlén, Barbro, Mihaltan, Florin, Sergejeva, Svetlana, Popović-Grle, Sanja, Sedlak, Vratislav, Lehtimäki, Lauri, Bourdin, Arnaud, Korn, Stephanie, Zervas, Eleftherios, Csoma, Zsuzsanna, Lúðvíksdóttir, Dora, Butler, Marcus, Canonica, Giorgio Walter, Grisle, Ineta, Bieksiene, Kristina, Ten Brinke, Anneke, Kuna, Piotr, Chaves Loureiro, Claudia, Nenasheva, Natalia M., Lazic, Zorica, Škrgat, Sabina, Ramos-Barbon, David, Leuppi, Joerg, Gemicioglu, Bilun, Bossios, Apostolos, Porsbjerg, Celeste M., Bel, Elisabeth H., Djukanovic, Ratko, Louis, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589318/
https://www.ncbi.nlm.nih.gov/pubmed/36299366
http://dx.doi.org/10.1183/23120541.00273-2022
_version_ 1784814278601080832
author Frix, Anne-Noelle
Heaney, Liam G.
Dahlén, Barbro
Mihaltan, Florin
Sergejeva, Svetlana
Popović-Grle, Sanja
Sedlak, Vratislav
Lehtimäki, Lauri
Bourdin, Arnaud
Korn, Stephanie
Zervas, Eleftherios
Csoma, Zsuzsanna
Lúðvíksdóttir, Dora
Butler, Marcus
Canonica, Giorgio Walter
Grisle, Ineta
Bieksiene, Kristina
Ten Brinke, Anneke
Kuna, Piotr
Chaves Loureiro, Claudia
Nenasheva, Natalia M.
Lazic, Zorica
Škrgat, Sabina
Ramos-Barbon, David
Leuppi, Joerg
Gemicioglu, Bilun
Bossios, Apostolos
Porsbjerg, Celeste M.
Bel, Elisabeth H.
Djukanovic, Ratko
Louis, Renaud
author_facet Frix, Anne-Noelle
Heaney, Liam G.
Dahlén, Barbro
Mihaltan, Florin
Sergejeva, Svetlana
Popović-Grle, Sanja
Sedlak, Vratislav
Lehtimäki, Lauri
Bourdin, Arnaud
Korn, Stephanie
Zervas, Eleftherios
Csoma, Zsuzsanna
Lúðvíksdóttir, Dora
Butler, Marcus
Canonica, Giorgio Walter
Grisle, Ineta
Bieksiene, Kristina
Ten Brinke, Anneke
Kuna, Piotr
Chaves Loureiro, Claudia
Nenasheva, Natalia M.
Lazic, Zorica
Škrgat, Sabina
Ramos-Barbon, David
Leuppi, Joerg
Gemicioglu, Bilun
Bossios, Apostolos
Porsbjerg, Celeste M.
Bel, Elisabeth H.
Djukanovic, Ratko
Louis, Renaud
author_sort Frix, Anne-Noelle
collection PubMed
description INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. RESULTS: Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. CONCLUSION: Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation.
format Online
Article
Text
id pubmed-9589318
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-95893182022-10-25 Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study Frix, Anne-Noelle Heaney, Liam G. Dahlén, Barbro Mihaltan, Florin Sergejeva, Svetlana Popović-Grle, Sanja Sedlak, Vratislav Lehtimäki, Lauri Bourdin, Arnaud Korn, Stephanie Zervas, Eleftherios Csoma, Zsuzsanna Lúðvíksdóttir, Dora Butler, Marcus Canonica, Giorgio Walter Grisle, Ineta Bieksiene, Kristina Ten Brinke, Anneke Kuna, Piotr Chaves Loureiro, Claudia Nenasheva, Natalia M. Lazic, Zorica Škrgat, Sabina Ramos-Barbon, David Leuppi, Joerg Gemicioglu, Bilun Bossios, Apostolos Porsbjerg, Celeste M. Bel, Elisabeth H. Djukanovic, Ratko Louis, Renaud ERJ Open Res Original Research Articles INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. RESULTS: Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. CONCLUSION: Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation. European Respiratory Society 2022-10-24 /pmc/articles/PMC9589318/ /pubmed/36299366 http://dx.doi.org/10.1183/23120541.00273-2022 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Original Research Articles
Frix, Anne-Noelle
Heaney, Liam G.
Dahlén, Barbro
Mihaltan, Florin
Sergejeva, Svetlana
Popović-Grle, Sanja
Sedlak, Vratislav
Lehtimäki, Lauri
Bourdin, Arnaud
Korn, Stephanie
Zervas, Eleftherios
Csoma, Zsuzsanna
Lúðvíksdóttir, Dora
Butler, Marcus
Canonica, Giorgio Walter
Grisle, Ineta
Bieksiene, Kristina
Ten Brinke, Anneke
Kuna, Piotr
Chaves Loureiro, Claudia
Nenasheva, Natalia M.
Lazic, Zorica
Škrgat, Sabina
Ramos-Barbon, David
Leuppi, Joerg
Gemicioglu, Bilun
Bossios, Apostolos
Porsbjerg, Celeste M.
Bel, Elisabeth H.
Djukanovic, Ratko
Louis, Renaud
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
title Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
title_full Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
title_fullStr Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
title_full_unstemmed Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
title_short Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
title_sort heterogeneity in the use of biologics for severe asthma in europe: a sharp ers study
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589318/
https://www.ncbi.nlm.nih.gov/pubmed/36299366
http://dx.doi.org/10.1183/23120541.00273-2022
work_keys_str_mv AT frixannenoelle heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT heaneyliamg heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT dahlenbarbro heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT mihaltanflorin heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT sergejevasvetlana heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT popovicgrlesanja heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT sedlakvratislav heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT lehtimakilauri heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT bourdinarnaud heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT kornstephanie heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT zervaseleftherios heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT csomazsuzsanna heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT luðviksdottirdora heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT butlermarcus heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT canonicagiorgiowalter heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT grisleineta heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT bieksienekristina heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT tenbrinkeanneke heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT kunapiotr heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT chavesloureiroclaudia heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT nenashevanataliam heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT laziczorica heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT skrgatsabina heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT ramosbarbondavid heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT leuppijoerg heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT gemicioglubilun heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT bossiosapostolos heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT porsbjergcelestem heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT belelisabethh heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT djukanovicratko heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy
AT louisrenaud heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy